Longeveron Inc. has been granted a U.S. patent covering the administration of its proprietary mesenchymal stem cells (MSCs) for the treatment of female patients with sexual dysfunction and for improving sexual quality of life. The newly issued patent, U.S. Patent No. 12,496,316, provides rights through 2038 and may be eligible for further term or regulatory exclusivity extensions. The patent relates to methods of administering effective amounts of isolated allogeneic MSCs to address female sexual dysfunction, a condition affecting up to 46% of women and often lacking effective treatment options. Longeveron plans to pursue licensing or partnering agreements for the development and commercialization of stem cell therapy for this indication.